Fig. 2

Mean healthcare costs in first and second year of life—cCMV₉₀ versus "representative" controls. (*) Drugs include costs of outpatient pharmaceuticals; costs of inpatient pharmaceuticals are included in inpatient costs. Incremental costs are shown with respective p-values. P-value < 0.05 was considered as statistically significant (Wilcoxon rank-sum test). Figures were commercially rounded, which may result in minor calculation differences. cCMV congenital cytomegalovirus, cCMV₉₀ infants with cCMV diagnosis during the first 90 days of life, “Representative” infants with no cCMV or CMV diagnosis in the observation period